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Cancer cells display changes that aid them to escape from cell death, sustain their proliferative powers, and shift their metabolism
toward glycolytic energy production. Mitochondria are key organelles in many metabolic and biosynthetic pathways, and the
adaptation of mitochondrial function has been recognized as crucial to the changes that occur in cancer cells. This paper zooms in
on the pathologic evaluation of mitochondrial markers for diagnosing and staging of human cancer and determining the patients’
prognoses.
1. Introduction
Mitochondria are membrane-enclosed cell organelles that
can be found in all human cells, except for the peripheral
red blood cells. An eukaryote cell contains around 1000
to 2000 mitochondria, with diameters varying between
0.5 and 1.0 μm. The mitochondrion is a key venue for
cellular metabolism and the powerhouse of the cell. As a
consequence, mitochondrial content is influenced by cellular
energy demand. Exercise training for instance, increases
the amount of mitochondria per fiber and the volume of
organelles in skeletal muscle tissue [1, 2].
1.1. Mitochondrial Metabolic Pathways. To understand the
crucial role played by mitochondria in cancer, it is necessary
to fully grasp the extent of their metabolic activity.
1.1.1. Glycolysis. Glycolysis is the sequence of cellular reac-
tions that converts glucose into pyruvate, with the con-
comitant production of a relatively small amount of energy.
Glycolysis occurs throughout the cell and is considered the
basis of all energy processes. The 2 ATP and 2 NADH
molecules it produces can enter the oxidative phosphoryla-
tion (OXPHOS) cycle, which then produces larger quantities
of ATP.
1.1.2. Oxidative Phosphorylation. In the Krebs or OXPHOS
cycle, sequential oxidation and reduction reactions take
place upon a chain of four multiprotein complexes: (1)
complex I is composed of 45 protein subunits and displays
NADH dehydrogenase activity. In the process, four hydrogen
ions are pumped out of the mitochondrial matrix. (2)
Complex II: the succinate dehydrogenase complex catalyzes
the oxidation of succinate to fumarate, with concomitant
reduction of ubiquinone. (3) In two cycles, complex III or
coenzymeQ cytochrome c oxidoreductase reduces coenzyme
Q, extracting 4 protons from the mitochondrial matrix.
(4) On complex IV or cytochrome c oxidase, electrons
are donated one at a time to cytochrome c and passed
on to O2, producing 2 H2O molecules. In addition to the
protons utilized in the reduction of O2, there is electron
transfer-linked transport of 2 protons from the matrix to the
mitochondrial intermembrane space.
The translocation of protons across the inner mitochon-
drial membrane, established by the respiratory chain, creates
an electrochemical gradient (Δψ) that is utilized by complex
V, the ATP synthase, to generate ATP from ADP and inor-
ganic phosphate. Complex V is composed of a catalytic com-
ponent on the matrix side (termed F1) and a hydrophobic
membrane component (termed F0) that contains the proton
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channel, linked by a stalk. The membrane-associated
OXPHOS complexes are co-assembled into higher-order
supercomplexes within the inner mitochondrial membrane
[3].
1.1.3. Tricarboxylic Acid Cycle. In the tri-carboxylic acid
(TCA) cycle, a series of chemical reactions generates energy
through the oxidization of acetate derived from carbo-
hydrates, fatty acids, and proteins. In addition, the cycle
provides precursors (amino acids for instance) as well as the
reducing agent NADH that is used in numerous biochemical
reactions. The series of oxidation reactions that occurs is
connected to the electron transport chain and generates
ATP. Acetyl CoA is oxidized by the pyruvate dehydrogenase
complex, which is located in the mitochondrial matrix.
1.1.4. Fatty Acid Oxidation. β-oxidation is the process by
which fatty acids are broken down to generate acetyl CoA,
the latter being the entry molecule for the TCA cycle. The
β-oxidation pathway involves 4 enzymes that are present
in the mitochondrial matrix and function in a repetitive
cycle. The process continues until the original fatty acid
molecule is completely degraded to acetyl coA. Acetyl coA
can subsequently enter the TCA cycle, undergoing oxidation
to CO2. Under conditions of starvation, acetyl coA can
alternatively be converted into ketones.
1.1.5. Urea Cycle. The urea cycle is a cycle of biochemical
reactions that produces urea from ammonia at the cost of
3 ATP molecules. The urea cycle consists of five reactions of
which the first two occur in the mitochondrial matrix.
1.1.6. Gluconeogenesis. Gluconeogenesis is a metabolic path-
way that generates glucose from substrates such as lactate,
glycerol, and glucogenic amino acids. It is one of the two
main mechanisms to keep blood sugar levels from dropping
when glucose intake is low and takes place mainly in the liver.
Gluconeogenesis is a pathway consisting of a series of eleven
enzyme-catalyzed reactions, starting in the mitochondria
with the formation of oxaloacetate by the carboxylation of
pyruvate. Oxaloacetate is reduced to malate using NADH, a
step required for its transportation out of the mitochondria,
and then reoxidized in the cytosol using NAD+. Oxaloacetate
is decarboxylated and then phosphorylated to form phos-
phoenolpyruvate using the enzyme phosphoenolpyruvate
carboxykinase. Phosphoenolpyruvate carboxykinase activity
is present in both the cytosol and the mitochondria. The
enzymes that convert phosphoenolpyruvate to glucose are
found in the cytosol. Transport of phosphoenolpyruvate
across the mitochondrial membrane is accomplished by
dedicated transport proteins.
1.2. Dual Genetic Origin of Mitochondria. A unique feature
of mitochondria is that these organelles contain their proper
genome. The human mitochondrial genome (mtDNA) is a
16 569 base-pair long circular DNA molecule that contains
genes for 13 structural subunits of oxidative phosphoryla-
tion: (1) 7 subunits of complex I encoded by ND1, ND2,
ND3, ND4L, ND4, ND5, and ND6 genes, (2) one complex
III subunit encoded by the CYTB gene, (3) 3 complex IV
subunits encoded by COXI, COXII, and COXIII genes, and
(4) 2 complex V subunits encoded by the ATP6 and ATP8
genes. The mtDNA also contains sequence information for
2 rRNA’s and 22 tRNA’s essential for translation of mito-
chondrial proteins. The mtDNA is exclusively maternally
inherited and a variety of polymorphisms is present in
the human population [4]. Multiple copies are present in
eachmitochondrion.WhenmtDNAwith diﬀerent sequences
coexists within a single cell or tissue, this is defined as
heteroplasmy. Many disease-causing mtDNAmutations have
been shown to display heteroplasmy, and the percentages of
mutated mtDNA determine the severity of mitochondrial
dysfunction [5].
1.3. Mitochondrial Morphology. Historically, mitochondria
were described as free-floating vesicles in the cell [6]. They
consist of an outer mitochondrial membrane (OMM) and
an inner mitochondrial membrane (IMM) that contains
convolutions termed cristae, forming the compartments of
intermembranous space (IMS) and mitochondrial matrix.
The development of cellular imaging techniques, however,
has since cast new light onto mitochondrial structure,
revealing it as a network of long tubules rather than a
collection of individual small vesicles. Mitochondria are
highly dynamic organelles that can fuse, divide, and form
an interconnected network throughout the cell that stretches
from the nucleus to the plasma membrane [7].
The mitochondrial network is shaped through the equi-
librium obtained by regulation of the mitochondrial fusion/
fission machinery. Two mitofusins, MFN1 and MFN2, are
dynamin-related GTPases located to the OMM. They can
form homo- and heterodimers and, fueled by GTP, will
make the OMM of adjacent mitochondria fuse. MFN2 is
also responsible for the tethering between mitochondria and
the endoplasmic reticulum. The related dynamin GTPase
optic atrophy 1 (OPA-1) is located to the IMM and controls
fusion at this level. Other proteins that are involved in
mitochondrial fusion are leucine zipper-EF-hand containing
transmembrane protein 1 (LETM1), phospholipase D, and
prohibitins. Dynamin-related protein 1 (DRP1) is a cytosolic
GTPase that, when recruited to the OMM, oligomerizes
forming ring-shaped structures and inducing mitochon-
drial constriction and subsequent fission. Mitochondrial
fission factor (MFF) is an adaptor of DRP1 on the OMM,
and mitochondrial elongation factor (MIEF) binds DRP1
inhibiting the latter’s activity [8]. Fission 1 (FIS1) can inter-
act and sequester MIEF function. Other proteins involved
in mitochondrial fission are endophilin B1, a fatty acyl
transferase that acts downstream of DRP1, mitochondrial
18 kDa protein (MTP18) [9], mitofusin binding protein
(MIB), and ganglioside-induced diﬀerentiation associated
protein 1 (GDAP1) [10].
Mitochondrial morphology and OXPHOS function are
strongly associated. Impaired OXPHOS function leads to
mitochondrial network fragmentation. Structural defects
in complex V lead to severe morphological alterations to
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the mitochondria [11], and the oligomeric state of F1F0
ATPsynthase determines cristae morphology [12].
2. Metabolic Cancer Markers
Cancer is strongly associated with perturbations in cellular
metabolism, with a characteristic metabolic shift toward
aerobic glycolysis in transformed cells.
2.1. Markers of Aerobic Glycolysis. In cancer cells, pyruvate
is abundantly transformed to lactate by aerobic glycolysis
[13], and the overexpression of glycolysis genes is the general
rule [14]. Physical association between glycolytic enzymes
and the mitochondrion has been firmly established using the
yeast cell model [15].
Enolases catalyze the conversion of 2-phosphoglycerate
to phosphoenolpyruvate. These enzymes are classically
regarded as cytosolic, yet they tightly associate with the
mitochondrial surface [16]. In human tissues, three genetic
loci, termed α, β, and γ, encode the diﬀerent enolase
isoforms. Enolase 1 is present in almost all adult tissues,
enolase 2 is found in neuronal and neuroendocrine tissues,
and enolase 3 is found mainly in muscle. They form hetero-
and homodimers that dehydrate 2-phosphoglycerate in the
glycolysis or the reverse reaction in the gluconeogenesis. The
enzyme is upregulated under stress conditions, via activation
of hypoxia-inducible factor-1 (HIF-1). Overexpression of α-
enolase is associated with tumor development and represents
a potential diagnostic and prognostic marker [17]. In breast
cancer, α-enolase gene expression correlates with tumor size
and shorter disease-free interval [18]. In head and neck [19]
and non-small-cell lung cancer [20], higher expression of α-
enolase is associated with poorer clinical outcome in patients.
Pyruvate kinase (PK) is a rate-limiting glycolytic enzyme
that converts phosphoenolpyruvate into pyruvate with the
generation of one ATP molecule. Its PKM1 and PKM2
isoforms are encoded by the same gene and are generated
by alternative splicing. PKM1 is found mainly in normal
cells, whereas PKM2 is an embryonic isoform expressed
in cancer cells [21]. Both plasma and fecal PKM2 can
be used as a marker for gastrointestinal cancer, showing
good diagnostic accuracy [22]. In addition, PKM2 plasma
levels appear predictive for disease severity and outcome.
Elevated levels have been found to associate with aggressive
breast carcinomas [23]. In breast cancers lacking caveolin-1,
PKM2 immunostaining is confined to the stromal cells and
sometimes the extracellular matrix [24].
Pyruvate, the end product of the glycolysis, enters
the mitochondria where it is transformed to acetyl CoA,
producing NADH and CO2. Acetyl CoA can subsequently
enter the TCA cycle. This process is regulated by the pyruvate
dehydrogenase complex (PDH), which is composed of the
E2 core bound to the E1 and E3 components. PDH activity
is controlled by pyruvate dehydrogenase kinases (PDK) 1 to
4, which phosphorylate and suppress the E1 subunit [25].
PDH levels are dramatically decreased in hepatomas [26]
and skin carcinomas [27]. While normal lung tissue stains
strongly for PDH and PDK1, a large proportion of cancer
cells in patients with non-small-cell lung carcinomas show
diminished expression. The lack of PDH expression was
shown to be associated with HIF-1α stabilization [28].
2.2. Oxidative Phosphorylation Markers. Warburg hypoth-
esized as early as the thirties of the last century that the
increased rates of aerobic glycolysis he observed in tumor
cells, might be due to their impaired respiratory capacities
[13]. Reduced respiration is indeed associated with cancer,
however, the OXPHOS is not always compromised as a
whole. For instance, the OXPHOS enzyme activities and pro-
tein levels are not uniformly decreased in breast cancer cell
lines. The spectrum of decrease is MCF7 (complexes II, III,
and V), T47D (complexes I, III), SKBr3 (complexes III, IV,
and V), andMDA-MB-231 (complexes I, III, IV, and V) [29].
Interestingly, the most aggressive breast cancer line (MDA-
MB-231) displays the broadest OXPHOS defect. In support, a
correlation was shown between low overall OXPHOS activity
and tumor aggressiveness in renal carcinoma [30].
2.2.1. Complex I. Complex I loss of function has been
shown many times in cancer tissues. In renal oncocytomas,
complex I activity is reduced by 50% [31] to 65% [32],
with blue native PAGE immunoblot revealing the lack of
assembled complex I. All 17 oncocytic thyroid adenomas
tested display greatly reduced or absent complex I subunit
NDUFS4 immunoreactivity, compared to expression levels
of complex II, III, IV, V, and porin, which are higher in the
tumor cells than in the adjacent normal tissue [33].
2.2.2. Complex II. A reduction of complex II activity is
associated with human cancer. In a series of 31 renal
carcinomas, complex II activities are 6-fold lower than in
controls [34]. Complex II activity was found decreased in
breast cancer cell lines [29].
2.2.3. Complex III. In addition to reduced activities [29],
complex III activation has also been reported in cancer.
Complex III subunits UQCRFS1 and UQCRH are overex-
pressed in a variety of tumors. The complex III subunits
Rieske iron-sulfur protein and Hinge protein are encoded by
the UQCRFS1 and UQCRH gene, respectively. Expression
studies reveal that transcripts of UQCRFS1 and UQCRH
are increased in breast tumors compared to normal breast
tissue. Immunohistochemical staining for UQCRFS1 shows
higher expression scores in breast cancer compared to benign
breast tissue [29]. Also, UQCRFS1 gene amplification has
been detected in breast tumors [35].
2.2.4. Complex IV. Both compromised and induced complex
IV function have also been observed in cancer. COXI,
COXII, and COXIV, mRNA levels are increased in hepatoma
compared with normal liver [36]. A proteomic study shows
a 2-fold upregulation of COXII protein in breast cancer
cells [37]. On the other hand, complex IV activity is 5-fold
decreased in renal carcinomas compared with controls [34].
Also, COXIII mRNA levels are lower in colonic carcinoma
versus normal mucosa samples [38]. Diﬀerential complex
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IV activity could be relevant to therapeutic outcome.
Adriamycin-resistant leukemia cells, for instance, contain
alterations in complex IV subunits and decreased activity of
the complex [39].
2.2.5. Complex V. The relationship between complex V
function and cancer appears to be complicated. Complex V
activity was shown to be reduced in high grade but normal
in low grade renal carcinomas [30], but another report did
not find a tumor grade correlation [34]. A proteomic study
shows a 2-fold increase of the ATP synthase f chain in breast
cancer cells [37].
2.3. Other Metabolic Markers. Being such a crucial venue of
metabolism, many other mitochondrial metabolic factors are
continuously surfacing as possible biomarkers for cancer. A
selection is discussed hereunder.
2.3.1. Hydratases. Fumarate hydratase (FH) is a nuclear-
encoded mitochondrial enzyme that takes part in the TCA
cycle, catalyzing the formation of L-malate from fumarate.
Mutations in the FH gene are associated with an autosomal
dominant tumor syndrome causing uterine, skin, and kidney
cancer [40] and hereditary leiomyomatosis and renal cell
cancer [41]. Mitochondrial enoyl-coA hydratase 1 catalyzes
the second step of the β-oxidation. Its expression is 10-fold
increased in a human gastric cancer cell line [42]. NAD-
dependent bifunctional methylenetetrahydrofolate dehydro-
genase/cyclohydrolase (MTHFD) regulates the biosynthesis
of tetrahydrofolate, providing precursors for nucleotides and
methylation reactions. There is a strong association between
MTHFD genetic variants and gastric [43] and bladder [44]
cancer risk. MTHFD2 protein content is 3-fold decreased in
breast cancer cell lines [37].
2.3.2. Dehydrogenases. Isocitrate dehydrogenases (IDH) are
important players in the exchange of metabolites within
the cell, and two IDH isoforms can be found within
the mitochondrion. NADP-dependent IDH2 has a role in
shuttling of electrons between the mitochondrion and the
cytosol. The mitochondrial matrix enzyme NAD-dependent
IDH3 is involved in the TCA cycle. Breast cancer cell lines
display high levels of IDH2, and expression is positively
associated with overall survival in breast cancer patients
[45], possibly due to enhanced reactive oxygen species (ROS)
protection.
2.3.3. Oxidases. Coproporphyrinogen III oxidase (HemN),
an enzyme required for heme synthesis, is present in the
IMM. It’s expression is increased in adriamycin-resistant
breast cancer cells [46].
3. Genetic Cancer Markers
Due to their genetic complexity, both the nuclear (nuDNA)
and the mitochondrial genome are suitable for investigation
in regard to carcinogenesis.
3.1. mtDNA Alterations in Cancer. The mtDNA is particu-
larly susceptible to mutations due to its proximity to ROS
generation and the relatively ineﬃcient DNA repair system
the mitochondrion possesses [47]. The frequency of mtDNA
mutations in cancer cells is 10-fold higher than nuDNA
mutations [48], and many alterations to the mtDNA that
can be detected in tumor cells potentially alter mitochondrial
function. Also, mtDNA alterations can often already be
detected in the premalignant stage. mtDNA is abundant and
readily detectable in blood, urine, and saliva samples, making
it an attractive subject for diagnostic investigations.
3.1.1. Alterations in ND Genes. The mtDNA encodes for
seven complex I subunits (ND1–ND6 and ND4L) and
alterations in cancer cells are plenty. Somatic mutations of
ND genes are associated with thyroid oncocytoma [49]. A
study of 10 colorectal cancer cell lines reveals 1 ND1, 1
ND4L, and 1 ND5 sequence alterations [50]. Of 45 colorectal
carcinomas tested, 3 contain ND1 and 3ND5 genemutations
[51]. Of 18 primary oral squamous cell carcinomas tested,
3 contain ND2, 1 ND3, and 1 ND4 somatic mutations
[52]. In a series of 15 patients with renal oncocytoma and
compromised complex I function, 4 patients harbor ND1, 3
patients ND4, and 3 patients ND5 sequence alterations. The
alterations are most often single-nucleotide insertions (6/10)
or deletions (3/10) [32]. In 31 urothelial cell carcinoma
patients, tumor cells contain ND1 (n = 2), ND2 (n = 3),
ND4 (n = 2), and ND6 (n = 1) frequency variations [53]. In
a study examining 38 bladder tumors, 73% contain at least
one base-pair alteration in the ND1 gene [54].
3.1.2. Alterations in the CYTB Gene. The mtDNA contains
one gene that encodes a structural unit of complex III,
namely, cytochrome b (CYTB). In 10 colorectal cancer cell
lines, 2 CYTB sequence alterations could be found [50].
Tumor cells from 3 of 31 patients with urothelial cell
carcinoma contain CYTB alterations [53]. In 81% of bladder
carcinomas, at least one base-pair substitution is present in
the CYTB gene [54]. In a human bladder cancer model,
CYTB alteration is shown to generate higher levels of ROS
and lead to increased tumor growth [55].
3.1.3. Alterations in COX Genes. The mtDNA encodes three
structural components of complex IV: COXI, COXII, and
COXIII. In 10 colorectal cancer cell lines, 1 COXI, 1 COXII,
and 1 COXIII sequence alterations are present [50]. Of
18 oral squamous cell carcinomas, 1 contains a COXIII
somatic mutation [52]. In 31 urothelial cell carcinoma
patients, tumor cells are found to contain altered sequence
in COXI (n = 2) and COXIII (n = 2) genes [53].
11% of prostate cancer patients harbor COXI mutations in
conserved sequences compared to less than 2% in healthy
controls [56].
3.1.4. Alterations in ATPase Genes. The mtDNA encodes two
structural units of complex V, being ATPase6 and ATPase8.
ATPase6 is central to the proton channel of the ATPase
[57]. Mutations in the ATP6 gene are present in 24 of
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39 patients with osteosarcoma [58]. In 1 of 31 urothelial
cell carcinoma patients, an ATP6 sequence variant is found
[53]. 71% of bladder tumors tested contain at least one
base-pair substitution in the ATP6 gene [54]. In a series
of 102 epithelial ovarian tumors, 12 contain ATP6 and 21
contain ATP8 sequence variations [59]. ATP6mutant cybrids
of prostate cancer cells display enhanced ROS generation
accompanied by increased tumorigenecity [56].
3.1.5. Alterations in tRNA Genes. The mtDNA encodes 22
transfer RNA (tRNA) molecules necessary for mitochondrial
protein translation. tRNA is the adaptor used to bridge the
four-letter genetic code in messenger RNA (mRNA) to the
twenty-letter code of amino acids present in proteins. In one
of the 15 tested patients with renal oncocytoma, the A3243G
mutation was shown in the mtDNA tRNALeu gene [32]. In
urothelial cell carcinoma patients, tumor cells contain tRNA
sequence variants in 4 of 31 patients tested [53].
3.1.6. Alterations in rRNA Sequences. The mtDNA encodes
both a small (12S) and a large (16S) ribosomal RNA (rRNA)
gene. In 10 colorectal cancer cell lines, 3 16S rRNA and 1 12S
rRNA sequence alteration are found [50]. In 31 urothelial
cell carcinoma patients, 5 tumors contain rRNA somatic gene
variations: 4/31 in the 16S and 1/31 in 12S rRNA [53].
3.1.7. mtDNA Displacement-Loop Alterations. Replication of
mtDNA starts in the displacement loop (D-loop) region
located between nucleotides 16024 and 16576. mtDNA repli-
cation involves DNApolymerase γ (POLG) and transcription
factor A mitochondrial (TFAM), the latter being the key
transcription factor regulating mtDNA copy numbers [60].
Mutations in the D-loop can therefore lead to decreased
mtDNA copy numbers and subsequent OXPHOS dysfunc-
tion and increased ROS. Intriguingly, the most frequent
mtDNA alterations in human cancers are in fact located in
the D-loop region [61]. mtDNA alterations within the D-
loop could be detected in 77% [52] or 64% [62] of oral
squamous cell carcinomas and 44% of colorectal carcinomas
(n = 45) [51]. Of 9 renal cell tumors tested, 3 contain D-
loop sequence changes [63]. In breast cancer patients, the
occurrence of D-loop mutations is associated with an older
onset age [64], suggesting that age-related DNA damage
contributes to the disease mechanism.
A homopolymeric C-stretch within the D-loop, between
nucleotides 303 and 315 termed the 310 microsatellite
sequence, is a relatively conserved region. It includes a repli-
cation origin for the mtDNA heavy-strand, and sequence
variations in D310 are thought to aﬀect mtDNA replication
[65]. Many reports have shown D310 sequence alterations
in human cancers. In 34% of rectal carcinomas (n =
38) and 38% of sigmoid carcinomas (n = 25), D310
sequence alterations could be detected [66]. In breast cancer
patients, 68% of ductal carcinomas in situ (n = 23)
and 71% of invasive ductal carcinomas (n = 26) harbor
D310 sequence alterations [67]. In 11 of 18 breast cancers,
mtDNAmutations could be detected, of which 42% are D310
alterations [68]. 38% of gallbladder carcinomas (n = 123)
contain D310 alterations [69] and 62% of multicentric
hepatocellular carcinomas [70].
D310 mutation detection could represent a potential
early marker for premalignant human disease. Histologically
normal breast epithelial cells, adjacent to invasive ductal
carcinomas that carry D310 mutations, already display D310
alterations [67]. D310 alterations are also present in normal-
appearing (46%) and dysplastic (57%) gallbladder epithelia
accompanying gallbladder carcinomas [69]. It seems that
D310 alterations are an early event in malignity, and
detection could serve as an early detection strategy. In
addition, D-loop alterations have been put forward as a
possible prognostic marker for therapeutic outcome. Three-
year survival rates of patients with stage III colorectal cancer
are 70% without and 47% with D-loop mutations. In
combination with fluorouracil as adjuvant chemotherapy,
the diﬀerence is even more pronounced, being 78% versus
45%, respectively [71].
3.1.8. Alterations in mtDNA Abundance. Each mitochon-
drion contains multiple copies of the mtDNA, and this
copy number changes in reponse to energy demands. Either
increased or reduced mtDNA content has been reported
in cancer cells [72, 73]. mtDNA content is elevated in
head and neck [74] and esophageal [75] squamous cell
carcinoma and increased in malignant compared to pre-
malignant lesions [76]. Also, mtDNA levels are increased
in papillary thyroid carcinomas [77], endometrial cancer
[78], and oncocytomas [79]. Quantitative real-time PCR
amplifying mtDNA-encoded COXI and nuDNA-encoded β-
actin revealed a significant increase of mtDNA content in
the tumors of 76% of urothelial cell carcinoma patients
compared to the matched lymphocytes [53]. Nonetheless,
increased mtDNA content does not appear to be firmly
associated with carcinogenesis. In prostate cancer, it has been
observed that cells with an amplified mtDNA copy number
coexist with cells displaying a diminished or depleted copy
number [80]. In a study that quantified mtDNA content
using RT-PCR with ND1 primers in 31 gastric cancers,
23% of patients displayed a significant increase, but 55%
displayed a significant decrease of mtDNA content [81].
Moreover, the relative ratio of mtDNA over nuclear 18S
rDNA, as determined by Southern blot, is 3-fold lower in
renal carcinoma tissues than in controls [34]. Also, mtDNA
content was found reduced in the majority of breast tumors,
with mean mtDNA content, as determined by quantitative
RT-PCR using ND1 gene primers, being significantly lower
than that of the adjacent nontumorous tissue [64]. In
lung cancer, mtDNA depletion has been associated with
progressive disease [82].
Circulating mitochondrial nucleic acids could be a prog-
nostic marker for cancer. Patients with prostate, head and
neck, kidney and colorectal cancer, and blood mitochondrial
RNA concentrations above the 95th percentile found in
healthy subjects demonstrate decreased survival after a two-
year follow-up period [83]. Also, mtDNA content may be
a potential biomarker for prediction of the response to
chemotherapy. Breast cancer patients with lower copy num-
ber of mtDNA have better disease-free survival than patients
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with high mtDNA content, when treated with anthracycline
after surgery [84]. Possibly, low mtDNA content enhances
ROS and sensitizes the cancer cells to anticancer agents.
3.2. nuDNA Alterations Aﬀecting Mitochondrial Function in
Cancer. The repertoire of nuclear-encoded genes involved
in mitochondrial function continues to expand [85]. They
include, but are not limited to, mutations in genes encoding
structural OXPHOS subunits, OXPHOS assembly factors,
and components of the mitochondrial protein translation
machinery. nuDNA alterations have not been studied as
extensively as mtDNA alterations, but are more and more
recognized in cancer. SNP-analysis of the mitochondrial bio-
genesis pathway (25 genes), for instance, reveals a pathway-
wide association with a risk of developing epithelial ovarian
carcinoma [86]. Mitochondrial biogenesis is crucial because
of the constant battle of the organelle against ROS and DNA
damage.
3.2.1. Complex I. The nuDNA encodes several structural
complex I subunits, as well as complex-specific assem-
bly factors. Single-nucleotide polymorphisms in NDUFA9,
NDUFS2, and NDUFB9 genes are associated with prostate
[87] and NDUFB10, NDUFA11, and NDUFA12 with epithe-
lial ovarian [86] cancer risk.
3.2.2. Complex II. Complex II contains four nuclear-encoded
structural subunits designated SDHA to D. The subunits are
imported into the mitochondria, where they are modified,
folded, and assembled to functional complex II. The genes
encoding complex II subunits behave as tumor suppressors.
Hereditary paraganglioma has been linked to SDHA [88],
SDHB [89], SDHC [90], and SDHD [91] gene mutations.
SDHB mutations have also been shown in pheochromocy-
toma [92] and renal cell carcinomas [93]. Also, mutations
in SDH assembly factor 2 (SDHAF2) cause head and
neck paragangliomas [94]. SDHAF2 is essential for the
incorporation of FAD cofactor in the SDHA subunit. It has
been suggested that loss of complex II function induces HIF,
which promotes glycolysis and angiogenesis and thus tumor
growth and survival.
3.2.3. Complex III. Of the 11 structural subunits that make
up complex III, 10 are encoded by nuclear genes. Genetic
amplification of the UQCRFS1 gene has been reported in
leukemia [95], ovarian [96], and breast carcinoma [35].
3.2.4. Complex IV. In addition to structural subunits, the
nuclear genome encodes many assembly factors necessary for
complex IV formation. Single-nucleotide polymorphisms in
the COX7A2 gene have been linked to an increased risk of
developing prostate cancer [97], while COX7A1 and COX8C
alterations have been shown to associate with epithelial
ovarian cancer risk [86].
3.2.5. DNA Polymerase γ. POLG is responsible for the
replication of the mtDNA, and mutations cause multiple
large scale deletions and mtDNA depletion, leading to com-
promised OXPHOS functioning. Mutations in the POLG
gene have been detected in breast cancers and are associated
with mtDNA depletion in cancer cells [98]. The POLG gene
contains a polymorphic CAG repeat of a dominant length
of 10. Men with homozygous deviations from this length
have an increased risk of developing seminomas [99]. The
percentage of the homozygous non-10 allele is significantly
higher in cancer patients than in the general population, yet
is only present in low frequencies.
4. Mitochondrial Stress Markers
4.1. ROS Damage Control. Mitochondrial respiration inher-
ently produces ROS, and OXPHOS dysfunction further
increases its generation. In cancer cells, a consistent increase
of ROS can be observed. NADPH oxidase 1, amajor source of
ROS in the cells, predominantly localizes to themitochondria
and is highly expressed in breast (86%) and ovarian (71%)
tumors [100]. To counter the damaging eﬀect of ROS,
cells contain a multilayered system of antioxidant defences
executed by three types of enzymes: superoxide dismutases
(SOD), peroxidases (POD), and catalases (CAT).
MnSOD is constitutively present in the mitochondrial
matrix, but expression can be further induced by hypoxia.
MnSOD levels are low or below the detection limit in
healthy human pleural mesothelium, but highly increased in
tumor biopsies of malignant mesothelioma [101]. MnSOD
levels are increased in ovarian cancer [102]. In breast
cancer patients, strong MnSOD staining can be observed
in neoplastic cells, moderate-to-strong staining in adjacent
hyperplastic ducts and weak-to-moderate staining in normal
epithelium [103]. A histochemical study on the other hand
reveals lower expression in breast cancer cells compared
to the adjacent normal epithelia [104]. MnSOD expression
levels have been put forward as a prognostic factor for
gliobastoma [105, 106].
Glutathione POD is present in diﬀerent cellular compart-
ments, including the mitochondria. A polymorphism variant
of the glutathione POD1 gene is associated with lung cancer
risk [107]. In women with papillary serous ovarian cancer,
serum glutathione POD3 levels are significantly lower than
in controls, and the decrease is stage-dependent [108]. In
endometrial adenocarcinoma on the other hand, glutathione
POD3 is uniformly downregulated regardless of tumor grade
or histopathological subtype, which would imply that it is an
early event in tumorigenesis [109].
Mitochondrial expression of CAT has been shown, and
in vitro studies have indicated that decreased levels of
CAT correlate with invasive and migratory capacities of cell
lines and resistance to chemotherapeutic drugs [110]. Gene
therapy that results in mitochondrial CAT overexpression
renders transgenic mice less susceptible to metastatic breast
cancer [111]. Thus, increasing the antioxidant capacity of the
mitochondrial compartment could be a rational therapeutic
approach.
Prolonged hypoxia and failing ROS neutralization acti-
vates HIF proteins that in turn increase the expression
of the oncogenes RAS, MYC, and p53. MYC stimulates
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mitochondrial biogenesis, which will increase ROS further.
Induction of p53 induces mitochondrial apoptotic pathways,
and mitochondrial p53 physically and functionally interacts
with the mtDNA and POLG. p53 provides exonuclease activ-
ity enabling error-repair, and thus functions as a guardian of
the mitochondrial genome [112]. Loss of p53 is a marker for
advanced progression in prostate cancer [113].
4.2. Apoptosis Markers. Mitochondria are regulators of apop-
totic processes. Oxidative stress accompanied by calcium
overload, ATP depletion, and elevated phosphate levels
induce mitochondrial permeability transition (MPT) with
formation of nonspecific MPT pores (MPTP). Three pro-
teins are key structural components of the MPTP: adenine
nucleotide translocase (ANT) in the IMM, cyclophilin D
in the matrix, and the voltage-dependent anion channel
(VDAC) in the OMM [114]. Opening of MPTP causes
mitochondria to become permeable to all solutes up to a
molecular mass of 1500Da. Pore opening results in mito-
chondrial dysfunction, through uncoupling of OXPHOS
from ATP hydrolysis. Osmotic forces make the mitochondria
swell and the OMM rupture, releasing apoptogenic proteins
into the cytosol. Released proteins include cytochrome c,
apoptosis inducing factor (AIF), and endonuclease and sec-
ond mitochondria-derived activator of caspases/direct IAP-
associated binding protein with low pI (Smac/DIABOLO),
which, in conjunction with apoptosis protease activating
factor (APEF-1), activate caspase 9. The ultimate result is
DNA fragmentation and cell death. Additionally, mitochon-
drial membrane permeability is further regulated by Bcl-
2 proteins, including the proapoptotic Bax, Bak, Bid, and
Bad [115]. Bax is a known tumor suppressor protein [116].
The MPTP, that contains both repressors and inducers of
apoptosis, has been ascribed a target for anticancer drugs
[117].
Repression of apoptosis is a hallmark of tumorigenesis
[118]. Many immunohistochemical markers of apoptosis
have become available to the pathologist, including cleaved
caspase 3 and AIF, and have become indispensable for tissue
evaluation. Cyclophilin D was found significantly increased
in tumors of the breast, uterus, and ovarium but not in kid-
ney, gastro-intestinal, and lung cancers [119]. Proapoptotic
Bcl-2 interacting protein 3-like (BNIP3L) immunostaining
is elevated in the stroma of human breast cancers that
lack caveolin-1 [120]. Cofilin, an inducer of the release of
cytochrome c, is a small cytoskeletal protein that depolymer-
izes actin filaments. Apoptosis is mediated through mito-
chondrial shuttling of actin- and cofilin-interacting protein
1 [121]. Gene associated with retinoid-interferon-induced
mortality-19 (GRIM-19) is a cell-death regulator that works
through inhibition of signal transducer and activator of
transcription 3 (STAT3). Loss or dysregulation of GRIM-19
provides growth advantage to cancer cells. Intriguingly, it
has been demonstrated that GRIM-19 localizes to OXPHOS
complex I [122], and that its dysfunction results in complex
I disassembly and disruption of electron transfer [123].
GRIM-19mRNA and protein expression are severely reduced
in primary renal cell [124], colorectal [125], and cervical
[126] carcinoma. In normal prostatic tissues, the epithelium
stains intensely, while in prostatic adenocarcinomas, GRIM-
19 staining is focally lost [124]. In lung cancer, GRIM-
19 expression is reduced and translocates to the nucleus.
GRIM-19 downregulation in non-small-cell lung carcinoma
correlates with advanced disease stage [127]. Delivery of
GRIM-19 has been put forward as a plausible therapeutic
approach [128].
4.3. Molecular Chaperones. Mitochondrial molecular chap-
erones play important roles in protein transport, protein
complex assembly, refolding of misfolded proteins, and,
when all else fails, sentencing proteins to degradation by
the proteasome. They represent a heterogeneous group
of proteins subdivided into families according to their
molecular weight: large HSP, HSP90, HSP70, HSP60, and
HSP40 and small HSP families. In cancer cells, the network of
molecular chaperones appears altered compared to normal
cells.
4.3.1. HSP90 Family. Molecular chaperones of the HSP90
gene family are considered indispensable regulators of
protein folding. The HSP90 proteins HSP86 and HSP84
are mainly found in the cytoplasm of normal cells, but
in contrast are found to accumulate in the mitochondrial
matrix and IMS of tumor cell mitochondria [129]. Bladder
specimens stain strongly forHSP90 in all cells, but in primary
bladder transitional cell carcinoma, loss of expression is
observed in 24% of tumors. In superficial bladder carcinoma,
loss of HSP90 expression is associated with the risk of
developing an infiltrating recurrence [130]. TNF receptor-
associated protein 1 (TRAP1) is amember of the HSP90 fam-
ily that is considered mostly mitochondrial. In vivo studies
in the rat have shown that TRAP1 protects against hypoxia,
by reducing generation of ROS, improving mitochondrial
complex IV activity, and preserving ATP levels [131].
TRAP1 expression is induced in tumor cells. As revealed by
immunohistochemistry, TRAP1 staining appears intense in
pancreas, breast, colon, and lung adenocarcinomas, while
normal matched epithelia stain weakly [132].
Accumulating evidence points to a protective role against
apoptosis for the HSP90 family. TRAP1 and HSP90 are
involved in the mitochondrial pathway that antagonizes the
proapoptotic activity of cyclophilin D [132]. This interaction
occurs in a multichaperone complex that is selectively
assembled in tumor cells and is not present in normal
mitochondria [133]. Also, TRAP1 has been shown to directly
interact with members of the MPTP, inhibiting its opening
and the subsequent release of cytochrome c [134].
4.3.2. HSP70 Family. The human HSP70 family encom-
passes a member present in the mitochondrial matrix and
two cytosolic members: HSP73 is largely constitutive, while
HSP72 can be induced by cellular stress. HSP70 levels
are increased in cancer cells, including osteosarcoma [135]
and renal cell carcinoma [136]. In urothelial carcinoma
of the bladder, HSP70 immunostaining is significantly
linked with tumor grade [137]. This upregulation increases
the tumorigenic potential through the chaperone’s anti-
apoptotic properties.
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4.3.3. HSP60 Family. In human cells, HSP60 is largely
but not exclusively mitochondrial and localizes to the
mitochondrial matrix and the OMM. HSP60 is constitu-
tively expressed, but its expression increases in response to
mitochondrial damage and mtDNA depletion [138]. The
chaperone appears to have both prosurvival and proapop-
totic functions, and the relationship between HSP60 and
tumor prognosis and clinical outcome remains unclear.
Upregulation has been described in several cancers including
colorectal [139] and cervical [140] carcinomas. Western
blot analysis revealed significantly higher HSP60 protein
levels in cervical cancer compared to normal tissue, but
semiquantitative RT-PCR showed no diﬀerence in expres-
sion of the corresponding mRNA [141]. HSP60 protein is
overexpressed in prostate cancers compared with normal
prostate epithelium and hyperplasia. Immunostaining is
relatively homogeneous, coarsely granular and confined
almost exclusively to neoplastic epithelial cells. Western
blotting analyses show that high Gleason score tumors have
significantly higher levels of HSP60 protein than tumors
of low to moderate Gleason score [142]. In oesophageal
squamous cell carcinoma [143] and ovarian cancer [144] on
the other hand, positive HSP60 expression correlates with
good prognosis.
4.3.4. Small HSP Family. HSP27 is mainly cytosolic, but a
small fraction localizes to the mitochondria. HSP27 expres-
sion may be a useful prognostic marker of poor survival
in human cancers. HSP27 is upregulated in the serum
of breast cancer [145] and ovarian cancer [146] patients
and correlates with poor clinical outcome. mRNA and
protein levels are significantly higher in epithelial ovarian
cancer with peritoneal metastasis than without [147]. A
clinical evaluation of breast cancer and melanoma patients
correlates expression of HSP27 with tumor aggressiveness
and decreased survival [148]. HSP10 staining is present in the
mitochondria and correlates with high grading of urothelial
bladder carcinoma [137].
5. Mitochondrial Membrane Markers
5.1. Mitochondrial Depletion and Proliferation Markers.
Mitochondrial membrane proteins can serve to quantify the
mitochondrial load of tumors, and porin (VDAC) is often
used as amarker formitochondrial abundance. Quantified to
porin content measured by Western blot, no obvious mito-
chondrial reduction was seen in renal carcinoma compared
to control kidney. However, citrate synthase activity, another
frequently used marker for mitochondrial load, was 2-fold
lower in renal carcinoma tissues [34]. Oncocytomas show a
5-fold increase of citrate synthase activity and an increase of
the number of mitochondria [30].
5.2. Mitochondrial Import Channels. Mitochondrial func-
tion is profoundly dependent on the import of cytosolic
proteins. Complex protein structures form channels that
allow preproteins to translocate from the cytosol to the
mitochondrial matrix. The proteins that constitute these
channels are the translocase of the outer mitochondrial
membrane (TOMM) and translocase of the inner mitochon-
drial membrane (TIMM) proteins [149]. TOMM20 selec-
tively stainsmetastatic breast cancer cells and is largely absent
from the adjacent metastatic lymph node stroma [150].
Proteomic analysis shows a 5-fold increase of TIMM17A
protein levels in breast cancer cells, and the increase could
be validated by western blot and immunohistochemistry.
The latter shows strong staining in ductal carcinoma in
situ and invasive ductal carcinoma of the breast, while the
adjacent normal epithelia and stromal cells are negative. All
normal breast tissues are TIMM17A negative. Quantitative
RT-PCR confirms significantly higher levels in invasive
carcinoma compared to normal breast tissue [151]. A recent
study confirms upregulation of TIMM17A mRNA, when
normalized against the housekeeping gene cytokeratin 19
[152]. Both studies have shown TIMM17A expression to
be associated with poorer disease-free and overall survival.
Thus, TIMM17A oﬀers a promising diagnostic as well as
prognostic marker for breast cancer patients.
5.3. Other Mitochondrial Membrane Proteins. Translocator
protein (TSPO), also known as peripheral-type benzodi-
azepine receptor, is a well-conserved protein located at the
OMM-IMM contact sites and is closely associated with
VDAC and ANT. TSPO has been shown to participate
in apoptotic processes but has been ascribed both anti-
and proapoptotic properties. Administering TSPO ligands
increases the antineoplastic properties of cytostatic drugs
in human hepatocellular cancer cells [153]. Overexpression
of TSPO is associated with aggressive tumor subtypes in
breast, colorectal, and prostate carcinomas and correlates
with advancing stages of malignancy. Metastatic breast
and colorectal adenocarcinomas manifest increased TSPO
expression relative to their primary malignancies. In con-
trast, adrenocortical hepatomas display decreased TSPO
levels compared to the strongly staining normal hepatocytes
[154].
6. Mitochondrial Morphology Markers
The classical way to study mitochondrial morphology is
transmission electron microscopy. Using such techniques,
changes in mitochondrial morphology have been shown to
accompany alterations in mitochondrial function. Increasing
evidence shows the involvement of mitochondrial dynamics
in cancer development, but the structural mitochondrial
alterations appear heterogeneous and nonspecific to neo-
plasias. In addition, in all instances where mitochondrial
pleomorphism could be observed, normal mitochondria
were equally present.
Mitochondrial morphological changes associated with
cancer are varied and include: (1) increased mitochondrial
mass as seen in breast carcinomas [49] and pancreatic
tumors [155] (2) reduced numbers and degradation to
mitochondrial remnants in hepatocellular carcinoma [156]
(3) swollenmitochondria as in clear cell carcinoma [157] and
undiﬀerentiated retinoblastoma [158] (4) elongated tubular
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Figure 1: Mitochondrial diagnostic and prognostic biomarkers and their dominant intracellular location. Bcl-2 interacting protein-3 like
(BNIP3L), fumarate hydratase (FH), gene associated with retinoid-interferon-induced mortality (GRIM), coproporphyrinogen III oxidase
(HemN), heat shock protein (HSP), inner mitochondrial membrane (IMM), isocitrate dehydrogenase (IDH), mitochondrial matrix (MM),
outer mitochondrial membrane (OMM), oxidative phosphorylation (OXPHOS), pyruvate dehydrogenase (PDH), pyruvate dehydrogenase
kinase (PDK), pyruvate kinase type M (PKM), peroxidase (POD), polymerase γ (POLG), translocase of the inner mitochondrial membrane
(TIMM), translocase of the outer mitochondrial membrane (TOMM), tumor necrosis factor-associated protein (TRAP), translocator
protein (TSPO).
mitochondria in aldosterone-producing adrenal cortical ade-
noma [159] and (5) aberrations to the cristae varying from
reduced amounts in osteosarcoma cell lines [160] to densely
packed villiform and lamelliform cristae in Warthin’s tumor
[161].
When comparing a human gastric cancer cell line with
normal rat gastric mucosal cells, electron microscopy reveals
a significant decrease in both the numbers per cell and the
size of mitochondria [162]. An ultrastructural study of renal
cancer observes most severe mitochondrial aberrations in
eosinophilic clear cell renal cell carcinomas, where most
mitochondria appear swollen with loose matrix and short
attenuated cristae [163]. Percentages of mitochondria with
damaged cristae are 72% in a primary mammary carcinoma
cell culture, compared to 20% in a control mammary
epithelial cell line [164].
Several cristae remodeling markers have been described
and include Mitofilin [165]. Many mitochondrial fusion/
fission factors are involved in maintaining mitochondrial
integrity. tBid binds to cardiolipin, a negatively charged
phospholipid present in the IMM [166, 167]. Optimal
mitochondrial membrane potential is necessary for mito-
chondrial fusion [168]. Cancers exhibit an imbalance of
mitochondrial fission factors. In tumor tissue from lung
cancer patients, increase of DRP1 is accompanied by decrease
of MFN2 levels when comparing with adjacent healthy tissue
[169]. Immunohistochemistry and immunoblotting reveals
DRP1 overexpression in 89% of tested lung adenocarcinomas
(n = 202). DRP1 is mostly found sequestered within
the nucleus [170]. Nuclear DRP1 overexpression correlates
with tumor staging, smoking, resistance to chemotherapy,
and worse prognosis. FIS1 is upregulated in subtypes of
melanoma [171].
7. Conclusions and Perspectives
Assaying mitochondrial factors has long been recognized
as a diagnostic approach for metabolic disorders. Con-
venient methods have been developed for human tissues
[172] and cultured skin fibroblasts [173, 174]. In addi-
tion, diagnostic and prognostic mitochondrial markers have
been developed for cancer. An overview is given in this
paper (Figure 1). These include classical histopathological
evaluation of mitochondrion-related proteins, as well as
molecular techniques. Detection of mtDNA alterations oﬀers
the advantage of allowing low invasive methods, including
analysis in urine for bladder cancer or saliva for head and
neck cancers [70]. Also, screening tools such as MitoChip
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oligonucleotide arrays [175] make it possible to screen for
many factors at the same time.
Mitochondria have not only become valuable subjects for
the early detection of cancer, but, moreover, may become
cellular targets for future cancer therapy. Mitocans, that
is, anticancer agents that act through the mitochondria,
provide a strategy for targeting of mitochondrial metabolism
and apoptotic processes. The vitamin E analog alpha-
tocopheryl succinate (alpha-TOS) is a mitocan that inhibits
the mitochondrial electron redox chain by interfering with
the ubiquinone-binding sites of complex II [176], by which
processes are suppressed that are essential for tumor neovas-
cularization [177]. The mitochondrially targeted analog of
alpha-TOS, termed MitoVES, is more potent in preventing
tumor neovascularization and suppressing cancer growth.
This selectivity is attributed to the greater mitochondrial
inner membrane potential of proliferating endothelial cells
and translates in reduced tumor progression in an in vivo
breast cancer model [178]. The clinic awaits results of
therapeutic trials with great interest.
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